Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of CKD-330 and D086 in Healthy Males
NCT03017950Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Dec 2016
- Primary completion
- Mar 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candesartan, amlodipine and atorvastatin in hypertension (HTN) and hyperlipidemia (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: AUCtau,ss of Candesartan and Amlodipine at Day 30 and AUCtau,ss of Atorvastatin and 2-hydroxy atorvastatin at Day 30. Started Dec 2016; status: completed.
02
Drugs
candesartanamlodipineatorvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT03017950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017950.